Jpmorgan Chase & CO Neurocrine Biosciences Inc Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
A detailed history of Jpmorgan Chase & CO transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 2,295,108 shares of NBIX stock, worth $311 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
2,295,108
Previous 1,735,543
32.24%
Holding current value
$311 Million
Previous $229 Million
38.42%
% of portfolio
0.03%
Previous 0.02%
Shares
12 transactions
Others Institutions Holding NBIX
# of Institutions
631Shares Held
94.4MCall Options Held
505KPut Options Held
343K-
Black Rock Inc. New York, NY13.8MShares$1.86 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.93MShares$1.34 Billion0.03% of portfolio
-
State Street Corp Boston, MA3.99MShares$540 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.25MShares$305 Million0.49% of portfolio
-
Morgan Stanley New York, NY2.07MShares$280 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...